NCT06790706
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06790706
Title IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5)
Acronym IMMUNORARE5
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hospices Civils de Lyon
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.